To view this email as a web page, click here.

A Look at the Clinical Benefits of the FDA's Expanded Access Program

A single-center evaluation of the FDA's Expanded Access program indicated broad use of the program among the center's patients, including a large percentage of pediatric patients.

Oral Duvelisib Potential New Option for Indolent Non-Hodgkin Lymphoma

The DYNAMO study investigated the oral PI3K gamma inhibitor duvelisib in heavily pretreated indolent non-Hodgkin lymphoma patients.

IN CASE YOU MISSED IT

FDA Approves Subcutaneous Trastuzumab Formulation for HER2+ Breast Cancer

The US Food and Drug Administration has approved the subcutaneous administration of trastuzumab for patients with HER2-overexpressing breast cancer.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.